Hiromichi Matsuoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiromichi Matsuoka has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
Rika Nakahara
National Cancer Center Hospital Tokyo Japan
11 shared publicationsSaho Wada
National Cancer Center Hospital Tokyo Japan
11 shared publications- Junji Yamaguchi
National Cancer Center Hospital Tokyo Japan
9 shared publications Eri Nishikawa
National Cancer Center Hospital Tokyo Japan
7 shared publicationsRyoichi Sadahiro
Department of Psycho-oncology, National Cancer Center Hospital, Tokyo, Japan
7 shared publicationsTatsuto Terada
National Cancer Center Hospital Tokyo Japan
7 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (11) , e73944
Dementia With Severe Psychiatric Symptoms Complicated by Family Neglect Treated via Home‐Visit Treatment: A Case Report
Barriers to necessary hospitalization can be significant in clinically complex cases involving family neglect and severe psychiatric symptoms. Home‐visit treatment with interprofessional collaboration may be an effective intervention, helping establish relationships with the patient and family, increasing awareness of the illness, and facilitating appropriate hospital care when needed.
- 15 November 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (11) , e73944
Open AccessDementia With Severe Psychiatric Symptoms Complicated by Family Neglect Treated via Home‐Visit Treatment: A Case Report
Barriers to necessary hospitalization can be significant in clinically complex cases involving family neglect and severe psychiatric symptoms. Home‐visit treatment with interprofessional collaboration may be an effective intervention, helping establish relationships with the patient and family, increasing awareness of the illness, and facilitating appropriate hospital care when needed.
- 6 October 2026
- Published by Wiley in The Journal of Dermatology
Non‐Pharmacological Psychosomatic Approaches to Patients With Atopic Dermatitis: A Delphi Consensus of Expert Opinions in Japan
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by persistent itch and a prolonged clinical course and can affect mental health and impair quality of life. Stress and anxiety exacerbate the symptoms of itch, leading to a vicious cycle that influences patient scratching behaviors and worsens disease prognosis. Dermatologists should consider psychosomatic correlations in patients with AD and provide psychosomatic intervention. However, standardized, consensus‐based non‐pharmacological psychosomatic approaches for patients with AD have not been established in Japan. This study sought to establish a Japanese consensus on non‐pharmacological psychosomatic approaches to patients with AD. Japanese experts in psychosomatic dermatology stated their level of agreement with 28 items in round 1 plus one added in round 2 (29 items in total) regarding psychosomatic approaches as non‐pharmacological approaches among patients with AD over Delphi rounds. Consensus was defined a priori as agreement from ≥ 75% of participants. The response rate was 17/21 (81.0%) in the first round and 17/17 (100%) in the second round. Twenty‐five statements were adopted over both rounds. Performance of medical interviews and physical examinations, recognition of patient efforts, and respect for the interpretive model of the patient categorized to establish a good therapeutic relationship showed agreement. Evaluation of pathology from physical and psychological perspectives (addictive scratching, building a bio‐psycho‐social [BPS] model and pathophysiological hypothesis) showed high‐level agreement. Indirectly promoting patient awareness of aggravating factors of AD and sharing the BPS model and pathophysiological hypothesis with the patient showed consensus. Further, 14 statements about the application of psychosomatic correlations to therapy showed agreement. In the second round, group therapy also gained consensus as a useful intervention. Our Delphi panel provides recommendations about psychosomatic interventions for patients with AD to standardize approaches in clinical practice and research.
- 6 October 2026
- Published by Wiley in The Journal of Dermatology
Non‐Pharmacological Psychosomatic Approaches to Patients With Atopic Dermatitis: A Delphi Consensus of Expert Opinions in Japan
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by persistent itch and a prolonged clinical course and can affect mental health and impair quality of life. Stress and anxiety exacerbate the symptoms of itch, leading to a vicious cycle that influences patient scratching behaviors and worsens disease prognosis. Dermatologists should consider psychosomatic correlations in patients with AD and provide psychosomatic intervention. However, standardized, consensus‐based non‐pharmacological psychosomatic approaches for patients with AD have not been established in Japan. This study sought to establish a Japanese consensus on non‐pharmacological psychosomatic approaches to patients with AD. Japanese experts in psychosomatic dermatology stated their level of agreement with 28 items in round 1 plus one added in round 2 (29 items in total) regarding psychosomatic approaches as non‐pharmacological approaches among patients with AD over Delphi rounds. Consensus was defined a priori as agreement from ≥ 75% of participants. The response rate was 17/21 (81.0%) in the first round and 17/17 (100%) in the second round. Twenty‐five statements were adopted over both rounds. Performance of medical interviews and physical examinations, recognition of patient efforts, and respect for the interpretive model of the patient categorized to establish a good therapeutic relationship showed agreement. Evaluation of pathology from physical and psychological perspectives (addictive scratching, building a bio‐psycho‐social [BPS] model and pathophysiological hypothesis) showed high‐level agreement. Indirectly promoting patient awareness of aggravating factors of AD and sharing the BPS model and pathophysiological hypothesis with the patient showed consensus. Further, 14 statements about the application of psychosomatic correlations to therapy showed agreement. In the second round, group therapy also gained consensus as a useful intervention. Our Delphi panel provides recommendations about psychosomatic interventions for patients with AD to standardize approaches in clinical practice and research.
- Open Access
Feasibility of a randomised controlled trial comparing opioid dose escalation with low-dose methadone addition for refractory cancer pain: JORTC-PAL23/NCCH2309 – protocol
Introduction: Methadone exerts analgesic effects through μ-opioid receptor affinity and N-methyl-D-aspartate receptor antagonism, which may benefit refractory cancer pain with neuropathic components. Methadone can be introduced by the ‘stop-and-go’ (SAG) method or the ‘add-on’ (AO) method, in which low-dose methadone is added to existing opioids. Observational studies suggest AO may improve pain control but no double-blind randomised controlled trial (RCT) has evaluated this approach. Therefore, the primary aim of this study is to assess the feasibility of conducting a double-blind RCT comparing methadone AO therapy with opioid dose escalation according to standard practice for refractory cancer pain while also exploring safety and preliminary efficacy signals. Methods and analysis: A two-centre, randomised, double-blind, two-arm feasibility trial will enrol 22 patients with advanced or recurrent cancer and inadequately controlled pain (oral morphine equivalent daily dose 60–300 mg). Participants will be allocated 1:1 to the methadone AO or opioid-escalation group using a web-based randomisation system with the minimisation method. The primary endpoint is the completion rate of the 2-week study treatment. Secondary outcomes include pain intensity (Brief Pain Inventory), time to adequate pain control, achievement of a personalised pain goal, adverse events (Common Terminology Criteria for Adverse Events (CTCAE)/Patient-Reported Outcomes version of the CTCAE) and quality of life (European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Core 15-PAL). Feasibility will be determined based on achieving a treatment completion rate of 70% or higher. Ethics and dissemination: The protocol was approved by the Certified Review Board of the National Cancer Centre Hospital (CRB3180008). Written informed consent will be obtained from all participants. The trial is registered in the Japan Registry of Clinical Trials. Results will be published in peer-reviewed journals and presented at international conferences. Trial registration number: jRCTs031240220.
Open AccessFeasibility of a randomised controlled trial comparing opioid dose escalation with low-dose methadone addition for refractory cancer pain: JORTC-PAL23/NCCH2309 – protocol
Introduction: Methadone exerts analgesic effects through μ-opioid receptor affinity and N-methyl-D-aspartate receptor antagonism, which may benefit refractory cancer pain with neuropathic components. Methadone can be introduced by the ‘stop-and-go’ (SAG) method or the ‘add-on’ (AO) method, in which low-dose methadone is added to existing opioids. Observational studies suggest AO may improve pain control but no double-blind randomised controlled trial (RCT) has evaluated this approach. Therefore, the primary aim of this study is to assess the feasibility of conducting a double-blind RCT comparing methadone AO therapy with opioid dose escalation according to standard practice for refractory cancer pain while also exploring safety and preliminary efficacy signals. Methods and analysis: A two-centre, randomised, double-blind, two-arm feasibility trial will enrol 22 patients with advanced or recurrent cancer and inadequately controlled pain (oral morphine equivalent daily dose 60–300 mg). Participants will be allocated 1:1 to the methadone AO or opioid-escalation group using a web-based randomisation system with the minimisation method. The primary endpoint is the completion rate of the 2-week study treatment. Secondary outcomes include pain intensity (Brief Pain Inventory), time to adequate pain control, achievement of a personalised pain goal, adverse events (Common Terminology Criteria for Adverse Events (CTCAE)/Patient-Reported Outcomes version of the CTCAE) and quality of life (European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Core 15-PAL). Feasibility will be determined based on achieving a treatment completion rate of 70% or higher. Ethics and dissemination: The protocol was approved by the Certified Review Board of the National Cancer Centre Hospital (CRB3180008). Written informed consent will be obtained from all participants. The trial is registered in the Japan Registry of Clinical Trials. Results will be published in peer-reviewed journals and presented at international conferences. Trial registration number: jRCTs031240220.
- Open Access
- 11 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e94381
Safety and Effectiveness of an Integrative Treatment of Acupuncture-Based Intervention in Survivors of Breast Cancer With Postmastectomy Pain Syndrome: Protocol for a Single-Center, Single-Arm Exploratory Trial
Background: Postmastectomy pain syndrome (PMPS) is a prevalent chronic pain condition that occurs after breast cancer surgery, often impairing quality of life in survivors of breast cancer. Despite its prevalence, no standardized treatment has been established. Acupuncture has been reported to be an efficacious intervention for the management of chronic pain and may be an effective treatment for PMPS. Objective: This study aims to explore the effectiveness and safety of integrative treatment of acupuncture-based intervention for PMPS. Methods: This is a single-center, single-arm, prospective interventional study. Eligible participants are patients with breast cancer who experience chronic postoperative pain in the chest, neck, or shoulder with a numerical rating scale (NRS) score ≥4, are at least 6 months postcurative treatment, have no evidence of disease recurrence, and are not receiving anticancer treatment at enrollment. Participants will receive the intervention once weekly for 12 sessions, followed by a 4-week observation period. The primary end point is the change in the average pain NRS score from baseline to week 16. Results: The study commenced in October 2023 and is scheduled to continue through March 31, 2027. The first participant was enrolled on October 24, 2023. As of the manuscript submission, 24 patients have been enrolled. Conclusions: This study will explore the potential role of an integrative treatment of acupuncture-based intervention in the management of PMPS. The results will contribute to the evidence base for acupuncture in PMPS and inform the design of future clinical studies.
- 11 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15 (1) , e94381
Open AccessSafety and Effectiveness of an Integrative Treatment of Acupuncture-Based Intervention in Survivors of Breast Cancer With Postmastectomy Pain Syndrome: Protocol for a Single-Center, Single-Arm Exploratory Trial
Background: Postmastectomy pain syndrome (PMPS) is a prevalent chronic pain condition that occurs after breast cancer surgery, often impairing quality of life in survivors of breast cancer. Despite its prevalence, no standardized treatment has been established. Acupuncture has been reported to be an efficacious intervention for the management of chronic pain and may be an effective treatment for PMPS. Objective: This study aims to explore the effectiveness and safety of integrative treatment of acupuncture-based intervention for PMPS. Methods: This is a single-center, single-arm, prospective interventional study. Eligible participants are patients with breast cancer who experience chronic postoperative pain in the chest, neck, or shoulder with a numerical rating scale (NRS) score ≥4, are at least 6 months postcurative treatment, have no evidence of disease recurrence, and are not receiving anticancer treatment at enrollment. Participants will receive the intervention once weekly for 12 sessions, followed by a 4-week observation period. The primary end point is the change in the average pain NRS score from baseline to week 16. Results: The study commenced in October 2023 and is scheduled to continue through March 31, 2027. The first participant was enrolled on October 24, 2023. As of the manuscript submission, 24 patients have been enrolled. Conclusions: This study will explore the potential role of an integrative treatment of acupuncture-based intervention in the management of PMPS. The results will contribute to the evidence base for acupuncture in PMPS and inform the design of future clinical studies.
- Open Access
- 26 January 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (1) , e70090
Zolpidem Withdrawal Delirium Developed as Severe Psychiatric and Physical Symptoms in a Patient With a History of Ovarian Cancer: A Case Report and Literature Review
Background: Zolpidem is a common medication for sleep disorders prescribed during or after cancer treatment. However, the possible risk of zolpidem withdrawal delirium does not seem to be well recognized by medical staff engaged in cancer treatment. Case Presentation: A female in her 50s with a diagnosis of ovarian cancer underwent bilateral oophorectomy 6 years earlier. No recurrence was observed after treatment with anticancer drugs. She had been prescribed zolpidem (10 mg/day, oral) by her attending physician for approximately 5 years, although she often took it 2–3 times the dose when her insomnia was severe. At X years, she was hospitalized due to abdominal pain from infectious enteritis, and zolpidem was discontinued. On Day 3 of hospitalization, however, she became extremely confused and disoriented with psychomotor agitation, delusions, and myoclonus. Laboratory findings, brain magnetic resonance imaging (MRI), and spinal fluid examination denied encephalitis and encephalopathy. Finally, the patient was diagnosed with zolpidem withdrawal delirium, and lemborexant was effective for her sleep disorders. She was discharged on Day 22 with no aftereffects. Conclusions: Cancer patients might be relatively more prone to zolpidem withdrawal delirium because of the possible Blood–Brain Barrier dysfunction derived from anticancer drug treatment or cancer. Oncologists and liaison psychiatrists need to prevent and detect zolpidem withdrawal delirium because it may be difficult to manage withdrawal delirium with severe psychiatric symptoms in cancer hospitals with no dedicated psychiatric ward.
- 26 January 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (1) , e70090
Open AccessZolpidem Withdrawal Delirium Developed as Severe Psychiatric and Physical Symptoms in a Patient With a History of Ovarian Cancer: A Case Report and Literature Review
Background: Zolpidem is a common medication for sleep disorders prescribed during or after cancer treatment. However, the possible risk of zolpidem withdrawal delirium does not seem to be well recognized by medical staff engaged in cancer treatment. Case Presentation: A female in her 50s with a diagnosis of ovarian cancer underwent bilateral oophorectomy 6 years earlier. No recurrence was observed after treatment with anticancer drugs. She had been prescribed zolpidem (10 mg/day, oral) by her attending physician for approximately 5 years, although she often took it 2–3 times the dose when her insomnia was severe. At X years, she was hospitalized due to abdominal pain from infectious enteritis, and zolpidem was discontinued. On Day 3 of hospitalization, however, she became extremely confused and disoriented with psychomotor agitation, delusions, and myoclonus. Laboratory findings, brain magnetic resonance imaging (MRI), and spinal fluid examination denied encephalitis and encephalopathy. Finally, the patient was diagnosed with zolpidem withdrawal delirium, and lemborexant was effective for her sleep disorders. She was discharged on Day 22 with no aftereffects. Conclusions: Cancer patients might be relatively more prone to zolpidem withdrawal delirium because of the possible Blood–Brain Barrier dysfunction derived from anticancer drug treatment or cancer. Oncologists and liaison psychiatrists need to prevent and detect zolpidem withdrawal delirium because it may be difficult to manage withdrawal delirium with severe psychiatric symptoms in cancer hospitals with no dedicated psychiatric ward.
- Open Access
- 10 December 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (1) , 22
Perioperative switching to lemborexant for prevention of delirium in older cancer patients with insomnia taking GABAA receptor agonists: a retrospective study
Purpose: Postoperative delirium (POD) occurs in about one-third of patients and the incidence increases with age. The rate of missed delirium is 60%–70%, and there has recently been a shift from early detection and treatment to preventive strategies to reduce risk. While GABA A receptor agonists (GRAs) are a risk factor for delirium, discontinuation may also worsen delirium through withdrawal or worsening of insomnia. This study aimed to evaluate the effect of switching from daily preoperative GRA therapy to lemborexant monotherapy on the incidence of postoperative delirium. Methods: A retrospective study was conducted in cancer patients aged ≥ 75 years who visited the Department of Psycho-Oncology at the National Cancer Center Hospital in Japan and were taking a GRA daily for insomnia before surgery under general anesthesia. Delirium was screened at least once daily with the Nursing Delirium Screening Scale on postoperative days 0–6 (positive if ≥ 2). We used a two-group intention-to-treat (ITT) framework, classifying patients according to a psycho-oncologist–verified preoperative switch to lemborexant. Results: Fifty patients satisfied eligibility. POD occurred in 1/17 (5.9%) in the Switch group and 15/33 (45.5%) in the Continue group; RD −39.6 percentage points (95% CI −59.9 to −19.2), RR 0.13 (95% CI 0.02–0.90), OR 0.08 (95% CI 0.01–0.63), p = 0.005. Conclusion: A preoperative switch policy to lemborexant monotherapy was associated with a lower observed risk of POD. Given the observational, unadjusted design, these associations are hypothesis-generating and cannot establish causality.
- 10 December 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (1) , 22
Open AccessPerioperative switching to lemborexant for prevention of delirium in older cancer patients with insomnia taking GABAA receptor agonists: a retrospective study
Purpose: Postoperative delirium (POD) occurs in about one-third of patients and the incidence increases with age. The rate of missed delirium is 60%–70%, and there has recently been a shift from early detection and treatment to preventive strategies to reduce risk. While GABA A receptor agonists (GRAs) are a risk factor for delirium, discontinuation may also worsen delirium through withdrawal or worsening of insomnia. This study aimed to evaluate the effect of switching from daily preoperative GRA therapy to lemborexant monotherapy on the incidence of postoperative delirium. Methods: A retrospective study was conducted in cancer patients aged ≥ 75 years who visited the Department of Psycho-Oncology at the National Cancer Center Hospital in Japan and were taking a GRA daily for insomnia before surgery under general anesthesia. Delirium was screened at least once daily with the Nursing Delirium Screening Scale on postoperative days 0–6 (positive if ≥ 2). We used a two-group intention-to-treat (ITT) framework, classifying patients according to a psycho-oncologist–verified preoperative switch to lemborexant. Results: Fifty patients satisfied eligibility. POD occurred in 1/17 (5.9%) in the Switch group and 15/33 (45.5%) in the Continue group; RD −39.6 percentage points (95% CI −59.9 to −19.2), RR 0.13 (95% CI 0.02–0.90), OR 0.08 (95% CI 0.01–0.63), p = 0.005. Conclusion: A preoperative switch policy to lemborexant monotherapy was associated with a lower observed risk of POD. Given the observational, unadjusted design, these associations are hypothesis-generating and cannot establish causality.
- Open Access
- 11 November 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (2) , 187-195
Medical cost of postoperative delirium after highly invasive cancer resection: a prospective cohort study
Background: Postoperative delirium (POD) is a common and serious complication, especially among older adults. The economic burden of POD, particularly in patients undergoing highly invasive cancer resection who are at high risk of delirium, remains unclear. We aimed to clarify the economic burden of subsyndromal delirium (SSD) and severe delirium in this population. Methods: We prospectively enrolled 281 adults undergoing highly invasive cancer resection and evaluated the impact of severe delirium and SSD diagnosed using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and the Delirium Rating Scale-Revised-98 severity scale. The primary outcome was diagnosis procedure combination (DPC) costs. Propensity score matching was performed to estimate the effect of delirium within a background-matched cohort, and generalized estimating equations with two-way cluster-robust standard errors were applied at both matched-set and patient levels. Sensitivity analyses were performed using direct medical costs (fee-for-service [FFS]). Results: Fifty-five patients (19.6%) developed severe delirium. DPC costs showed no significant mean difference, whereas total FFS costs were significantly higher in severe delirium (mean difference: US$2364, 95%CI: US$122 ~ US$4606). Component analyses indicated higher costs for prescriptions, infusions, wound-related procedures, and laboratory tests. SSD had no significant economic impact. Conclusion: Severe postoperative delirium after highly invasive cancer resection was associated with increased FFS expenditures, particularly for prescriptions, infusions, wound care, and laboratory tests, whereas no significant differences were observed in DPC costs. Findings underscore the importance of preventing severe delirium.
- 11 November 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (2) , 187-195
Open AccessMedical cost of postoperative delirium after highly invasive cancer resection: a prospective cohort study
Background: Postoperative delirium (POD) is a common and serious complication, especially among older adults. The economic burden of POD, particularly in patients undergoing highly invasive cancer resection who are at high risk of delirium, remains unclear. We aimed to clarify the economic burden of subsyndromal delirium (SSD) and severe delirium in this population. Methods: We prospectively enrolled 281 adults undergoing highly invasive cancer resection and evaluated the impact of severe delirium and SSD diagnosed using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and the Delirium Rating Scale-Revised-98 severity scale. The primary outcome was diagnosis procedure combination (DPC) costs. Propensity score matching was performed to estimate the effect of delirium within a background-matched cohort, and generalized estimating equations with two-way cluster-robust standard errors were applied at both matched-set and patient levels. Sensitivity analyses were performed using direct medical costs (fee-for-service [FFS]). Results: Fifty-five patients (19.6%) developed severe delirium. DPC costs showed no significant mean difference, whereas total FFS costs were significantly higher in severe delirium (mean difference: US$2364, 95%CI: US$122 ~ US$4606). Component analyses indicated higher costs for prescriptions, infusions, wound-related procedures, and laboratory tests. SSD had no significant economic impact. Conclusion: Severe postoperative delirium after highly invasive cancer resection was associated with increased FFS expenditures, particularly for prescriptions, infusions, wound care, and laboratory tests, whereas no significant differences were observed in DPC costs. Findings underscore the importance of preventing severe delirium.
- Open Access
- 6 October 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (4) , e70063
Organic Psychosis due to Lung Cancer Metastasis Accompanied by Severe Psychiatric Symptoms Treated With Blonanserin Transdermal Patch: A Case Report and Literature Review
Background: Organic psychosis associated with brain metastasis from cancer occasionally presents with psychiatric symptoms such as delusions or violent behavior. In these cases, however, psychotropics may not be sufficiently effective, and their continuous use may also be difficult due to side effects. Besides, regular oral administration of psychotropics becomes more difficult when medication refusal develops. Case Presentation: A man in his 80s. At X‐1 years, lung cancer was found to have metastasized to the right frontal lobe, with no apparent psychiatric symptoms. At X years, however, the patient was hospitalized because of consciousness disturbance, and new brain metastases in the right parietal and occipital lobes were detected. Irritability, violent behaviors, and delusions became dominant and required physical restraint. Refusal to take oral medications was also noted. Blonanserin transdermal patch (40 mg/day) was started along with an intravenous drip of haloperidol, and he became mentally calm, although psychiatric symptoms persisted with fluctuations. His mental status was finally stabilized with blonanserin transdermal patch (80 mg/day) with no side effects, leading to hospital discharge on Day 53 after admission. Conclusions: Blonanserin transdermal patch may be effective for organic psychosis associated with brain metastasis. Because it can be used in cases where oral medication is difficult and has relatively few side effects, such as hypotension and extrapyramidal symptoms, it may be a helpful option for oncologists and liaison psychiatrists.
- 6 October 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (4) , e70063
Open AccessOrganic Psychosis due to Lung Cancer Metastasis Accompanied by Severe Psychiatric Symptoms Treated With Blonanserin Transdermal Patch: A Case Report and Literature Review
Background: Organic psychosis associated with brain metastasis from cancer occasionally presents with psychiatric symptoms such as delusions or violent behavior. In these cases, however, psychotropics may not be sufficiently effective, and their continuous use may also be difficult due to side effects. Besides, regular oral administration of psychotropics becomes more difficult when medication refusal develops. Case Presentation: A man in his 80s. At X‐1 years, lung cancer was found to have metastasized to the right frontal lobe, with no apparent psychiatric symptoms. At X years, however, the patient was hospitalized because of consciousness disturbance, and new brain metastases in the right parietal and occipital lobes were detected. Irritability, violent behaviors, and delusions became dominant and required physical restraint. Refusal to take oral medications was also noted. Blonanserin transdermal patch (40 mg/day) was started along with an intravenous drip of haloperidol, and he became mentally calm, although psychiatric symptoms persisted with fluctuations. His mental status was finally stabilized with blonanserin transdermal patch (80 mg/day) with no side effects, leading to hospital discharge on Day 53 after admission. Conclusions: Blonanserin transdermal patch may be effective for organic psychosis associated with brain metastasis. Because it can be used in cases where oral medication is difficult and has relatively few side effects, such as hypotension and extrapyramidal symptoms, it may be a helpful option for oncologists and liaison psychiatrists.
- Open Access
- 3 October 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (4) , e70062
Potential Effectiveness of Yokukansan and Lemborexant as Alternative Candidates to Benzodiazepines to Prevent Benzodiazepine Withdrawal Delirium in the Cancer Perioperative Period: A Case Report and Literature Review
Background: Benzodiazepine withdrawal delirium is a serious problem, and several candidates have been proposed to manage benzodiazepine withdrawal, such as valproic acid and carbamazepine, up to now. However, it is not always possible to use these candidates during the cancer perioperative period due to the risk of oversedation, and new candidates are being awaited. Case Presentation: A woman in her late 80s was prescribed lorazepam 1.0 mg/day and brotizolam 0.25 mg/day for persistent anxiety and insomnia following the death of her husband and son. She had been receiving these medications for 3 years; however, they were ineffective, and she began consuming double the prescribed dose to manage her symptoms. Additionally, problematic drinking behavior was also acknowledged. Three months before the cancer surgery, the first author and her primary physician collaborated; lorazepam was gradually reduced to 0.5 mg/day, while yokukansan (5.0 g/day) and lemborexant (5.0 mg/day) were introduced instead. Her mental status stabilized, and surgery was performed as planned with no adverse effects. Postoperative and benzodiazepine withdrawal delirium were not observed. Conclusion: The combination of yokukansan and lemborexant may be an effective replacement for benzodiazepines in terms of their effects on 5‐hydroxytryptamine‐related mechanisms and regulation of the sleep cycle. During the cancer perioperative period, physicians may consider the gradual replacement or reduction of benzodiazepines with yokukansan and lemborexant before the surgery to avoid possible benzodiazepine‐related delirium.
- 3 October 2025
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 45 (4) , e70062
Open AccessPotential Effectiveness of Yokukansan and Lemborexant as Alternative Candidates to Benzodiazepines to Prevent Benzodiazepine Withdrawal Delirium in the Cancer Perioperative Period: A Case Report and Literature Review
Background: Benzodiazepine withdrawal delirium is a serious problem, and several candidates have been proposed to manage benzodiazepine withdrawal, such as valproic acid and carbamazepine, up to now. However, it is not always possible to use these candidates during the cancer perioperative period due to the risk of oversedation, and new candidates are being awaited. Case Presentation: A woman in her late 80s was prescribed lorazepam 1.0 mg/day and brotizolam 0.25 mg/day for persistent anxiety and insomnia following the death of her husband and son. She had been receiving these medications for 3 years; however, they were ineffective, and she began consuming double the prescribed dose to manage her symptoms. Additionally, problematic drinking behavior was also acknowledged. Three months before the cancer surgery, the first author and her primary physician collaborated; lorazepam was gradually reduced to 0.5 mg/day, while yokukansan (5.0 g/day) and lemborexant (5.0 mg/day) were introduced instead. Her mental status stabilized, and surgery was performed as planned with no adverse effects. Postoperative and benzodiazepine withdrawal delirium were not observed. Conclusion: The combination of yokukansan and lemborexant may be an effective replacement for benzodiazepines in terms of their effects on 5‐hydroxytryptamine‐related mechanisms and regulation of the sleep cycle. During the cancer perioperative period, physicians may consider the gradual replacement or reduction of benzodiazepines with yokukansan and lemborexant before the surgery to avoid possible benzodiazepine‐related delirium.